Combination therapy consisting of a glucagon-like peptide-1 receptor agonist (GLP1-RA) and basal insulin has emerged as an effective therapeutic option in the management of longstanding type 2 diabetes (T2DM)1, 2. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.